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Introduction {#S0001}
============

The development of colorectal cancer (CRC) is a multi-step process characterized by the accumulation of genetic alterations ([@CIT0001]). The evolution of colorectal cancer from polyps was first proposed by Morson ([@CIT0002]). Since the seminal publication of Vogelstein and Fearon ([@CIT0003]), we understand that most colorectal cancers arise in a multistep process progressing from mucosal hyperplasia to adenomas and carcinomas. The transformation of normal colonic epithelium to cancer is a multi-step process which is characterized by activating oncogenes and inactivating tumor suppressor genes. *Kras* (Kirsten rat sarcoma viral oncogene homologue) is a small GTPase (guanosin triphosphate cleaving enzyme) involved in intracellular signal transduction. It is a member of MAP kinase (MAPK) pathway ([@CIT0004]). *Kras* mutations lead to the deregulation of *Kras* protein activity, which results in the loss of GTPase activity and gain of oncogenic activity ([@CIT0005]). Specific mutations in the *Kras* gene leads to the formation of constitutively active protein, which triggers the transduction of proliferative and/or differentiative signals, even in the absence of extracellular stimuli ([@CIT0006]). Mutations in the *Kras* gene which are responsible for malignant transformation are point mutations in exons 2 and 3. *Kras* mutations are observed in approximately 37.4% of the Iranian patients with colorectal cancer.

Mutations in the *Kras* gene contribute at an early stage to the development in the colon tumourigenesis pathway ([@CIT0007]). *Kras* mutations occur in both microsatellite instable (MSI) in about 20% and Microsatellite stability (MSS) in about 35% subsets of sporadic CRC ([@CIT0008], [@CIT0009]). There have been approximately 3000 kras point mutations in colorectal cancer reported in the literature ([@CIT0010]). According to a previous study in Iran, most mutations were in codons 12 and 13 therefore, theses codons were examined. This confirms that codons 12 and 13 are preferentially involved in Iranian population as well ([@CIT0007]).

The aim of the study was to evaluate point mutations in exon 2 and 3 *Kras* gene in 95 carcinomas and polyps samples, furthered by the comparison of mutations profile in the polyp and tumor samples. Moreover, the MSI status in both groups was examined. Finding the probable mutation and most frequent MSI marker will be useful for early detection of sporadic colorectal cancer.

Patients and Methods {#S0002}
====================

This investigation was a case series study. Samples of cancer and polyps tissues were collected from 95 patients with sporadic colorectal cancers who underwent colonoscopy in Taleghani hospital Tehran from June 2008 to December 2009. The colonoscopy results were confirmed by pathological examinations. Patients with FAP and HNPCC or individuals with familial background were excluded. The use of patient samples was approved by the local ethics committee at Research Center for Gastroenterology and Liver Disease. The patient panel was comprised of 73 men and 22 women, age ranging from 13 to 85 years with a median 49 years. Samples were taken immediately after resection and placed in liquid nitrogen. Genomic DNA was obtained from all colorectal fresh tissue using QiaGen kit. Patients characteristics are presented in [Table 1](#T0001){ref-type="table"}. The 493 bp region in the exon 2 and 402 bp in exon 3 of *Kras* gene that encompasses the mutation hotspots were amplified by PCR using specific forward and reverse primer, and Taq DNA polymerase ([Table 1](#T0001){ref-type="table"}, [Figure 1](#F0001){ref-type="fig"}, [2](#F0002){ref-type="fig"}).

###### 

Specific primers for exon 2 and 3

  Name      Gene     Primer Sequence               Tm   Size
  --------- -------- ----------------------------- ---- ------
  F-exon2   *Kras*   5′-GACCCTGACATACTCCCAAG-3′    63   493
  R-exon2   *Kras*   5′-TACAGTTCATTACGATACACG-3′   63   494
  F-exon3   *Kras*   5′-GACTGTGTTTCTCCCTTCTC-3′    59   402
  R-exon3   *Kras*   5′-TTTCAATCCCAGCACCACCAC-3′   59   402

![PCR-product related to exon2](GHFBB-4-070-g001){#F0001}

![PCR-product related to exon3](GHFBB-4-070-g002){#F0002}

The PCR was conducted with denaturing step at 94 ºC for 5 min, then 30 sec at 94 ºC, 30 sec at 56/63 ºC and 30 sec at 72 ºC for 30 cycles, followed by a final 5 min at 72 ºC. The PCR products were then subjected to direct sequencing using the same primers, and all mutations were confirmed by sequence originating from both the upstream and downstream primers.

Direct sequencing was performed using fluorescent dideoxy on ABI sequencing 3130 XL according to manufacturer instructions. Samples were then subjected to direct sequencing of single-strand PCR product using the Big Dye Terminator v1.1 cycle sequencing kit and the ABI Prism 3130XL genetic analyzer (Applied Biosystems). All products were sequenced bidirectionally. The electropherograms were processed using Lasergene software version 6 (DNA star). Microsatellite analysis using fluorescence labeled primers and automated DNA sequencer (ABI 3130XL Applied Biosystems, Foster City, CA, USA) were performed. Five human mononucleotide microsatellite, NR-24, NR-21, NR-27, BAT-25 and BAT-26 were used as the markers ([@CIT0011]).

Microsatellite analysis using five fluorescent-labeled primers were performed according to following PCR condition, 94 ºC for 5 min, then 30 sec at 94 ºC, 40 sec at 55 ºC and 30 sec at 72 ºC for 35 cycles, followed by a final 7 min at 72 ºC and automated DNA sequencer. Analysis of MSI status was based on multiplex amplification of the 5 quasimonomorphic mononucleotide repeat microsatellite ([@CIT0011]). As a result of Microsatellite instability, MSI was considered when one or more than one marker was altered but in MSS no marker was changed.

Results {#S0003}
=======

*Kras* mutations in exons 2 and 3 were evaluated in 95 patients with colorectal cancer including 47 polyps and 48 tumors.

In polyp samples three (6.4%) mutations were detected. The mutations were in codon 12 and 13. They were three different types of mutations, Gly13Ala, Gly13Gly and Gly12Asp. Furthermore, we detected the MSI status of all polyps using pentaplex set of microsatellite markers. Our finding showed 8 (17%) polyps samples with MSI and 39 (83%) samples with MSS ([Table 2](#T0002){ref-type="table"}, [3](#T0003){ref-type="table"}).

###### 

Characteristics of samples with mutation

  Patient No.   Location Age   Sex   Pathology results   Mutation        MSI-result               
  ------------- -------------- ----- ------------------- --------------- ------------------------ ----------------
  3T            F              43    colon               Adenocacinoma   c.35 G\>A, p.Gly12 Asp   MSI-L (NR-21)
  26T           F              57    colon               Adenocacinoma   c.38 G\>A, p.Gly12 Asp   MSS
  40T           F              51    colon               Adenocacinoma   c.35 G\>A, p.Gly12 Asp   MSI-L ( NR-21)
  75T           F              58    colon               Adenocacinoma   c.35G\>A, p.Gly12 Asp    MSS
  80T           M              80    rectum              Adenocacinoma   c.35 G\>A, p.Gly12 Cys   MSS
  81T           F              56    colon               Adenocacinoma   c.35 G\>A, p.Gly12 Asp   MSS
  124P          M              61    rectum              Adenoma         c.37 G\>T,p.Gly13 Asp    MSI-L (NR-25)
  45P           F              43    colon               Adenoma         c.35 G\>C, p.Gly13 Ala   MSS
  57P           F              43    rectum              Adenoma         c.37 T\>A, p.Gly12       MSS

MSI-L : MSI Low; MSS: MSI Stable; P= polyp; T=tumor

###### 

MSI results related to tumor and polyp specimens

  Patients No.   Type of Samples   MSI Results   Changed MSI marker
  -------------- ----------------- ------------- --------------------
  3              Tumor             MSI-L         (BAT-25)
  6              Tumor             MSI-L         (NR-21)
  8              Polyp             MSI-L         (NR-21)
  10             Polyp             MSI-H         (NR-21), (NR-24)
  24             Polyp             MSI-L         (BAT-25)
  29             Polyp             MSI-L         (NR-21)
  40             Tumor             MSI-L         (NR-21)
  41             Tumor             MSI-L         (NR-24)
  50             Polyp             MSI-L         (NR-24)
  55             Polyp             MSI-L         (NR-21)
  62             Polyp             MSI-L         (NR-21)
  79             Tumor             MSI-L         (NR-21)
  124            Polyp             MSI-L         (BAT-25)

Six out of 48 (12.5%) carcinoma specimens exhibited *Kras* mutation including five in codon 12 (Gly12Asp) and one in codon 13 (Gly13Cys). All of the *Kras* amino acid change in codon 12 was glycine to aspartic acid (G12A). Five out of six (83.4%) mutations occurred in females and just one (16.6%) of them happened in a male. MSI analysis revealed that 5 MSI (10.4%) and 43 (89.6%) MSS ([Table 2](#T0002){ref-type="table"}, [3](#T0003){ref-type="table"}).

Furthermore, we could detect 9 intronic mutations in 48 tumor samples including five int.2271A\>C (55.6%), three int.2271C (33.3%) and one int.2271T\>C (11.1%). While in 47 polyp samples 15 intronic mutations were found. They consist of, 13 int.2271A\>C (86.7%) and two int.2271C. (13.3%) ([Table 4](#T0004){ref-type="table"}).

###### 

Profile of intronic mutations in polyp and tumor samples

  Patients No.   Intronic Mutations   MSI assay
  -------------- -------------------- ----------------
  1T             Int.2271A\>C         MSI-L (BAT-25)
  3T             Int.2271A\>C         MSS
  12P            Int.2271A\>C         MSS
  22T            Int.2271A\>C         MSS
  32P            Int.2271A\>C         MSS
  39P            Int.2271A\>C         MSS
  41T            Int.2271A\>C         MSI-L (NR-24)
  42P            Int.2271A\>C         MSS
  46P            Int.2271A\>C         MSS
  48P            Int.2271A\>C         MSS
  49P            Int.2271A\>C         MSS
  52P            Int.2271A\>C         MSS
  54P            Int.2271C            MSS
  58P            Int.2271C            MSS
  60P            Int.2271A\>C         MSS
  62P            Int.2271A\>C         MSI-L(NR-21)
  64T            Int.2271C            MSS
  66P            Int.2271A\>C         MSS
  69P            Int.2271A\>C         MSS
  72T            Int.2271T\>C         MSS
  75T            Int.2271C            MSS
  76T            Int.2271A\>C         MSS
  79T            Int.2271A\>C         MSI-L(NR-21)
  80T            Int.2271C            MSS

As [Table 2](#T0002){ref-type="table"} shows location of 5 out of 6 tumors with *Kras* mutation were in colon and only one tumor was detected in rectum. In contrast, 2 out of 3 polyps with *Kras* mutation were located in rectum and just one of them was determined in colon.

Of the 6 tumors with *Kras* mutations, 5 (83%) were G to A (Gly12Asp) and one was (17%) G to C (Gly12Cys). The type of *Kras* mutation was investigated in each MSI status. The frequency of G to A transition mutations in MSI-L and MSS was identical but they were higher than in MSI-H cancer. There was not any significant correlation between polyps or tumors with mutation and individuals clinical features (data was not shown) ([Table 2](#T0002){ref-type="table"}).

Discussion {#S0004}
==========

Mutations in the *Kras* oncogene are thought to occur at an early stage in the adenoma-carcinoma sequence, with the frequency of mutations increasing with the adenoma size in Western countries, with an age-adjusted incidence of 49 out of 100,000 per year. Colorectal cancer is one of the most frequent malignant human tumors however, in Iranian population CRC incidence rate is 6-7.9 per 100,000 persons/ year ([@CIT0007], [@CIT0012]--[@CIT0014]). These reports reflect that such incidence is remarkably lower than the rates reported in Western countries. This study investigated the ratio of *Kras* exon 2 and 3 in adenoma and adenomcarcinoma tissues in order to compare the mutations in two types of samples.

Replacement of glycine 12 of *Kras* with any amino acid, except proline, causes the biochemical activation of *Kras* by the reduction of its intrinsic GTPase activity of *Kras* ([@CIT0015]). Substitution of glycine 12 with proline renders *Kras* resistant to the catalysis of GAPs yet increases intrinsic GTPase activity, which is biologically significant in hydrolyzing GTP to GDP and reverting *Kras* back to its inactive form. This phenotype is not aggressive in nature ([@CIT0016]).

Comparing the frequency of *Kras* mutations highlighted, it is found that the frequency of *Kras* mutations detected in polyps is not statistically different from the frequency observed in MSI and MSS colorectal tumors.

Various studies in colorectal cancer have suggested that *Kras* codon 12 and 13 mutations are generally predictive of a poorer prognosis, with evidence being presented for mutation-specific prognostic as well as histopathology correlates ([@CIT0013]--[@CIT0016]).

The most frequent of exonic mutation was related to Gly12Asp. It could be considered as a biomarker before chemotherapy and also to evaluate prognosis. We could find Gly12Asp is a common mutation in tumor and polyp samples.

The rate of mutation in intronic region in polyp samples was higher than mutation rate in tumor samples. Therefore it is confirmed that these regions probably are not located in alternative splicing of the kras gene. Five of the 6 mutations that were identified in tumor samples were missense and led to the substitution of glycine to aspartate.

Our finding in respect of the most frequent mutation, Gly12Asp, in the studied population is compatible with the results revealed from Italian population. However, it was in contrast with another study from Iranian population in a similar investigation ([@CIT0007]).

These G → A transition mutations occurred in two ways - either by misreplication of the unrepaired endogenously produced O6-methylguanidine DNA methyltransferase (MGMT) from faulty S-adenosylmethionine methylation or due to exposure to nitrosamines ([@CIT0017]--[@CIT0019]). In this respect other DNA repair systems, such as O6 methylguanine-DNA methyltransferase activity, are linked to the inability to protect from G to A transition in *Kras* induced by alkylating agents ([@CIT0020], [@CIT0021]). It has been suggested that other repair systems could also contribute to this repair mechanism ([@CIT0021]). Further grouping of Kras mutations with regard to type and nucleotide position was shown to be significantly less frequent. The most frequent of MSI marker in this study was NR-21. In summary, we could consider mutation Gly12Asp in exon 2 as a biomarker to prediagnosis susceptible individuals before tumorgenesis. Nevertheless, how the Kras mutation may specifically modulate intracellular signaling is not well understood and remains a matter of ongoing research.
